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Abstract 20 
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative 21 
bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) 22 
producers, especially strains carrying the widely disseminated class A enzymes, are required. 23 
Relebactam, a diazabicyclooctane (DBO) BLI is in phase-3 clinical trials in combination with 24 
imipenem, for treatment of infections by multi-drug resistant Enterobacteriaceae. We show 25 
that relebactam inhibits five clinically-important class A SBLs (despite their differing spectra 26 
of activity), representing both chromosomal and plasmid-borne enzymes, i.e. the extended 27 
spectrum β-lactamases L2 (inhibition constant 3 μM) and CTX-M-15 (21 μM); and the 28 
carbapenemases, KPC-2, -3 and -4 (1 - 5 μM). Against purified class A SBLs, relebactam is 29 
an inferior inhibitor compared to the clinically approved DBO avibactam, (9 to 120-fold 30 
differences in IC50). Minimum inhibitory concentration assays indicate relebactam potentiates 31 
β-lactam (imipenem) activity against KPC-producing Klebsiella pneumoniae with similar 32 
potency to avibactam (with ceftazidime). Relebactam is less effective than avibactam in 33 
combination with aztreonam against Stenotrophomonas maltophilia K279a. X-ray crystal 34 
structures of relebactam bound to CTX-M-15, L2, KPC-2, KPC-3 and KPC-4 reveal its C2 35 
linked piperidine ring can sterically clash with Asn104 (CTX-M-15) or His/Trp105 (L2 and 36 
KPCs), rationalizing its poorer inhibition activity compared to avibactam, which has a 37 
smaller C2 carboxyamide group. Mass spectrometry and crystallographic data show slow, 38 
pH-dependent relebactam desulfation by KPC-2, -3 and -4. This comprehensive comparison 39 
of relebactam binding across five clinically-important class A SBLs will inform the design of 40 
future DBOs with the aim of improving clinical efficacy of BLI:β-lactam combinations. 41 
  42 
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Introduction 43 
 44 
A major determinant of drug resistance among Gram-negative pathogens is production of β-45 
lactamases, a large enzyme family whose members collectively hydrolyze all β-lactam 46 
antibiotics, including cephalosporins and last-resort carbapenems. β-Lactamases are divided 47 
into four main classes (A-D) based upon their sequences (1); classes A, C and D are serine-β-48 
lactamases (SBLs), while class B are the zinc-dependent metallo-β-lactamases (MBLs). SBLs 49 
hydrolyze antibiotics via formation of a hydrolytically labile ‘acyl’-enzyme intermediate, 50 
whilst MBL catalysis proceeds without a covalent intermediate (2). 51 
 52 
Of particular clinical importance are the widely disseminated class A SBLs, including the 53 
mobile, plasmid-encoded extended-spectrum CTX-M and carbapenem-hydrolyzing KPC 54 
families (both produced in opportunistic Gram-negative bacteria such as Klebsiella 55 
pneumoniae, Pseudomonas aeruginosa, and Escherichia coli (3, 4)), as well as 56 
chromosomally-encoded L2 from Stenotrophomonas maltophilia (a lung colonist of cystic 57 
fibrosis patients, (5, 6)). CTX-M and KPC production significantly threatens current 58 
antimicrobial chemotherapy (7, 8). CTX-M-15 is one of the most important members of the 59 
CTX-M extended-spectrum β-lactamase (ESBL) family, with a wide spectrum of catalytic 60 
activity (3, 8). Of the KPC carbapenemases, KPC-2, KPC-3 and KPC-4 are the most 61 
prevalent in resistant Enterobacteriaceae, differing from KPC-2 by single or double point 62 
substitutions at positions 104, 240 and 274 (KPC-3 H274Y; KPC-4 P104R/V240G) that 63 
change β-lactam specificity, especially toward the oxyimino-cephalosporin ceftazidime (7). 64 
L2 (an SBL) is one of two intrinsic β-lactamases, with L1 (an MBL), which together provide 65 
resistance to all β-lactams making S. maltophilia one of the most extensively drug resistant 66 
pathogens in the clinic and one of the most difficult to treat (5). 67 
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 68 
Three classical β-lactam-based β-lactamase inhibitors (BLIs), i.e. clavulanic acid (9), 69 
sulbactam and tazobactam, are used extensively to potentiate β-lactam activity (10). 70 
Inhibition is achieved through formation of (an) irreversible, covalent adduct(s) with the 71 
catalytic serine of SBLs. These inhibitors have clinically useful (10) potency against class A 72 
SBLs, but not typically against enzymes of classes C or D. Since their introduction some 73 
class A SBLs have accumulated mutations resulting in inhibitor resistance (11), whilst 74 
enzymes such as KPC show reduced susceptibility to inhibition (12). These observations 75 
highlight the need for novel BLIs effective against a wider range of -lactamases. 76 
 77 
The diazabicyclooctanes (DBOs), including avibactam (13), relebactam (14), and others (15-78 
17), are a new BLI class with improved activity against a wider range of SBL targets 79 
compared to  classic BLI scaffolds. Avibactam and relebactam contain the same bicyclic 80 
DBO core, differing in their side chains; relebactam contains an additional piperidine ring at 81 
C2 (Figure 1). DBOs inhibit SBLs through covalent formation of a carbamyl ester to the 82 
active-site serine concomitant with DBO ring opening (Figure 1). By contrast to clavulanic 83 
acid, binding is reversible, with decarbamylation and recyclization observed in CTX-M-15 84 
(18, 19), TEM-1 (13) and KPC-2 (13), as indicated by using ‘acyl’-exchange between two 85 
serine-β-lactamases. Mass spectrometry of avibactam binding to KPC-2 shows slow 86 
hydrolysis over 24 hr, likely following desulfation of the substrate (20). However, under 87 
similar conditions relebactam desulfation by KPC-2 was not observed (16), with molecular 88 
dynamics suggesting this enhanced relebactam stability results from repositioning of active 89 
site water molecules (21, 22). 90 
 91 
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In 2015 a ceftazidime-avibactam combination (Avycaz/Zavicefa) was approved for the 92 
treatment of complicated urinary tract and abdominal infections. This combination expands 93 
ceftazidime activity to encompass Gram-negative bacteria producing ESBLs and KPCs. More 94 
recently, an imipenem-relebactam combination is in phase-3 clinical trials, restoring the 95 
imipenem sensitivity of some resistant K. pneumoniae and P. aeruginosa (22). However, as 96 
with classical BLIs, avibactam resistance is emerging due to mutations/deletions in the β-97 
lactamase target (11, 23); several laboratory generated mutants have provided insight into 98 
potential mechanisms for avibactam and likely relebactam resistance (24). 99 
 100 
Structural investigations of relebactam are limited to the class C β-lactamase AmpC from 101 
Pseudomonas aeruginosa at 1.9 Å resolution (PDB 4NK3 (14)). Here, we investigate the 102 
structural basis of relebactam inhibition of 5 class A β-lactamases, correlating the results with 103 
differences in hydrolytic performance. The ESBLs CTX-M-15 (3) and L2 (25) confer 104 
resistance to penicillins, first-, second- and third-generation cephalosporins and the 105 
monobactam aztreonam, but are unable to hydrolyze carbapenems; while the hydrolytic 106 
capabilities of the KPC carbapenemases (KPC-2, KPC-3 and KPC-4) extend to the potent 107 
‘last resort’ carbapenems (7, 26). We also provide biochemical and microbiological data to 108 
investigate the differences in DBO inhibition across these enzyme families that will inform 109 
the design of future inhibitor generations. 110 
  111 
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Results and Discussion 112 
 113 
Relebactam Restores Imipenem Susceptibility of KPC-producing K. pneumoniae but is 114 
Less Effective Against S. maltophilia 115 
 The imipenem:relebactam combination (Merck) is currently undergoing phase 3 clinical 116 
trials, in particular for treatment of serious infections caused by carbapenem-resistant 117 
Enterobacteriaceae (ClinicalTrials.gov identifier: NCT02452047). In vitro studies have 118 
shown that both the ceftazidime:avibactam and imipenem:relebactam combinations are 119 
effective against clinical Enterobacteriacae isolates producing either KPC-2 or KPC-3 (27, 120 
28). However, other KPC variants vary more profoundly in their activities against specific β-121 
lactams (7), whilst relebactam activity against the non-fermenting species S. maltophilia is 122 
little explored. Accordingly, we compared susceptibilities of recombinant K. pneumoniae 123 
Ecl8 (29) producing the three most prevalent KPC variants, KPC-2, KPC-3 or KPC-4, to 124 
determine efficacy of relebactam combinations against SBL variants with different β-lactam 125 
hydrolyzing capabilities, and extended these experiments to include the clinical S. 126 
maltophilia K279a isolate. S. maltophilia causes myriad multi-drug resistant infections, often 127 
in immunocompromised patients and is therefore a particularly challenging target for 128 
antimicrobial therapy (6). Recently an avibactam:aztreonam combination proved successful 129 
in the treatment of several S. maltophilia strains (30), we investigate whether this activity is 130 
reflected with a relebactam:aztreonam combination. 131 
 132 
β-Lactam MICs for KPC variants expressed in K. pneumoniae Ecl8 range from 16 mg. L-1 to 133 
128 mg. L
-1
 for ceftazidime and 0.5 mg. L
-1 
(KPC-4)
 
to 16 mg. L
-1 
or 64 mg. L
-1 
for imipenem 134 
(Table 1). This range of MICs is reflected in previously determined kcat values (7) and 135 
relative MICs and hydrolysis rates (31) for KPC variants with both substrates. Despite these 136 
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differences, imipenem MICs are lowered to ≤0.5 mg. L-1 in all KPC producers in the presence 137 
of 4 mg. L
-1
 relebactam (Table 1), similar to the efficacy of a ceftazidime:avibactam 138 
combination. Both combinations can therefore be successful in treating strains producing the 139 
range of KPCs (with variable β-lactam hydrolyzing capabilities) in clinical, pathogenic 140 
Enterobacteriaceae.  By way of contrast, the S. maltophilia K279a clinical isolate (which 141 
produces both L1 (an MBL) and L2 (an SBL)), is resistant to both imipenem and the 142 
imipenem:relebactam combination (Table 1). We ascribe this to the presence of the L1 MBL, 143 
that is able to hydrolyze imipenem and is not inhibited by DBOs
 
(25). However, we, and 144 
others (30), have recently demonstrated that several strains of S. maltophilia (including 145 
K279a) can be inhibited with the monobactam aztreonam (which is not hydrolyzed by L1) 146 
combined with a non-classical BL I(25),((30). Indeed, an avibactam/aztreonam combination 147 
has been shown to be effective in treating a S. maltophilia infection in the clinic (30). 148 
Accordingly, we investigated the combination of aztreonam with relebactam against S. 149 
maltophilia K279a. Addition of relebactam lowers aztreonam MICs from 256 mg. L
-1 
to 8 150 
mg. L
-1 
(Table 1), but this compares unfavorably with avibactam, for which aztreonam MICs 151 
were lowered to 2 mg. L
-1 
(25). Thus, whilst effective against KPC-producing K. 152 
pneumoniae, when compared to avibactam, relebactam combinations (in particular with 153 
aztreonam) appear to be less effective against S. maltophilia.  154 
 155 
Relebactam is a Potent Inhibitor of Class A β-Lactamases in vitro 156 
Prior kinetic characterization (21) reveals relebactam to be a potent, micromolar, competitive 157 
inhibitor of KPC-2. We characterized the inhibition by relebactam, determining values for 158 
IC50, Kiapp (the apparent dissociation constant for the inhibitory complex as determined from 159 
Dixon plots (32)), k2/ K  (the apparent second-order rate constant for the onset of 160 
carbamylation by relebactam) and koff (rate of recovery of free enzyme), of five class A β-161 
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lactamases, the ESBLs CTX-M-15 and L2 and the carbapenemases KPC-2, KPC-3 and KPC-162 
4 (Figure 2 and Figures S1-S4) and compared these values with those for avibactam. The 163 
IC50 values (Table 2) determined after 10 minutes’ pre-incubation with inhibitor indicate that 164 
avibactam potently inhibits CTX-M-15 (3.4 nM), with potency decreasing 3-fold for KPC-2 165 
(IC50 10 nM) and KPC-4 (9.3 nM), 5-fold for L2 (15 nM) and 8-fold for KPC-3 (29 nM). 166 
Relebactam is substantially less potent than avibactam for each enzyme: by 9-fold (KPC-3), 167 
22-fold (KPC-2), 31-fold (L2), 98-fold (KPC-4) or 119-fold (CTX-M-15). The trends in 168 
avibactam and relebactam inhibition across these 5 enzymes are not consistent, for example 169 
CTX-M-15 is the most sensitive to avibactam (lowest IC50), but the least sensitive to 170 
relebactam (highest IC50, Table 2). Importantly, our data indicate that for the tested enzymes 171 
relebactam is consistently a substantially inferior inhibitor compared to avibactam (IC50 230 - 172 
910 nM, compared to 3.4 - 29 nM Table 2). Furthermore, the > 30-fold increase in IC50 173 
between avibactam and relebactam for L2 likely explains the difference in effectiveness of 174 
the respective aztreonam combinations against S. maltophilia K279a. However, against KPC-175 
expressing K. pneumoniae, relebactam combinations are as effective as those with avibactam, 176 
suggesting that, in organisms more permeable than S. maltophilia, differences in in vitro 177 
potency between the two DBOs do not translate into effects on MIC for their respective 178 
combinations.  179 
 180 
More detailed investigation of the time-dependence of relebactam inhibition (Table 3) 181 
showed that Kiapp  values, derived from Dixon plots based upon progress curves of initial rates 182 
of nitrocefin hydrolysis for enzyme:relebactam mixtures that had not been pre-incubated, 183 
generally reflect the IC50, with the exception of CTX-M-15, which has a relatively high 184 
Kiapp  of 21 μM. We consider this high value to reflect the atypically slow carbamylation of 185 
the enzyme by relebactam, with a second order rate constant for carbamylation k2/ K of 540 186 
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M
-1
 s
-1
 (Table 3). These values are also consistent with others’ recent reports of Kiapp values 187 
for relebactam inhibition of KPC-2 (2.3 μM; (21)) and the Pseudomonas-Derived 188 
Cephalosporinase-3 (PDC-3) enzyme (3.4 μM; (33)). 189 
 190 
Of the three KPC variants studied, KPC-4 has the highest apparent inhibition constant for 191 
relebactam (Kiapp 4.8 μM, compared to essentially identical Kiapp values for KPC-2 (1.2 µM) 192 
and KPC-3 (1.5 µM)). Differences between the three KPC variants are noticeable in their 193 
carbamylation rate constants k2/ K; with values for KPC-2 (4500 ± 220 M
-1
 s
-1
) noticeably 194 
faster than for KPC-3 (2100 ± 140 M
-1
 s
-1
) or KPC-4 (1100 ± 190 M
-1
 s
-1
). The effect of this 195 
is however ameliorated by a reduction of ~4.5 fold in off-rate for both of these variants 196 
compared to KPC-2. For L2 (Kiapp 2.7 µM) both the second order carbamylation rate constant 197 
(4000 ± 620 M
-1
 s
-1
), and off-rate (0.00055 ± 0.00021s
-1
) are relatively high. Overall 198 
differences in carbamylation rate across the five SBLs tested span almost one order of 199 
magnitude, whilst those in off-rate extend to < 5-fold (Table 3). 200 
 201 
The Structural Basis for Relebactam Inhibition of Class A β-Lactamases 202 
To investigate the molecular basis for relebactam inhibition of class A β-lactamases, and to 203 
identify structural explanations for differences in potency, we soaked crystals of CTX-M-15, 204 
L2, KPC-2, KPC-3 and KPC-4 with relebactam. For comparison, we also describe crystal 205 
structures of native KPC-3 and KPC-4 at 1.22 and 1.42 Å resolution (Table S3, Figures S5A 206 
and S5B). Comparison of these structures confirms that, compared to KPC-2, the H274Y and 207 
P104R/V240G substitutions do not result in large global conformational changes (Figure 208 
S5C, Table S5), or induce significant perturbations of the active site (Figure S5D).  209 
 210 
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Relebactam co-complex structures were obtained after 16-hour soaks for CTX-M-15 (1.12 Å, 211 
P212121), L2 (1.78 Å, P212121), KPC-2 (1.04 Å, P21212), KPC-3 (1.06 Å, P21212) and KPC-4 212 
(1.04 Å, P21212) (Table S3). We also obtained a crystal structure for a KPC-4 relebactam 213 
complex from data collected after a 1-hour soak. For all of these complex structures there was 214 
clear Fo-Fc difference density in the active site into which relebactam could be modelled 215 
(Figure 3) with ligand real-space correlation coefficients (RSCCs) all greater than 0.93 216 
(Table S4). This combination of high resolution and strong difference density enabled us to 217 
model the bound inhibitor with a high degree of confidence and enabled us to identify 218 
alternative ligand conformations and structures where these were present. For L2, electron 219 
density consistent with a single conformation of relebactam (refined at full occupancy) was 220 
observed in one of the two molecules in the asymmetric unit (Chain B). Consistent with 221 
previous observations for other potent L2 inhibitors in this crystal form we observe a non-222 
covalently bound molecule from the crystallisation solution (D-serine) in the chain A active 223 
site(25). In CTX-M-15, relebactam could be refined in two conformations, with occupancies 224 
of 0.49 and 0.51. In the KPC variants, structures obtained from diffraction datasets collected 225 
after exposing crystals to relebactam for 16 hours were observed to contain both intact and 226 
desulfated (i.e. in the imine form) relebactam in the active site, at variable occupancies. For 227 
comparison, a KPC-4 structure obtained after the crystal was exposed to inhibitor for just 1 228 
hour revealed only intact relebactam covalently bound in the active site.  229 
 230 
Relebactam Interactions with Class A β-Lactamases 231 
Crystal structures of all five class A SBLs tested here reveal relebactam covalently attached 232 
to the nucleophilic serine 70 (Figure 3, Figures S6-S8). Binding causes no apparent global 233 
conformational changes (for comparison, RMSDs between the relevant structures are 234 
provided in Table S5) and no large changes in any of the active sites compared to those of 235 
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the native, un-complexed enzymes. Importantly, the positioning of the ‘deacylating’ water 236 
(Wat1) is apparently little affected by relebactam binding (Figure 5D, Figures S6-S8). As 237 
seen in previous DBO complex structures (16, 19, 25), relebactam binds as a ring-opened 238 
carbamoyl-enzyme complex (13, 14), whereby the six-membered ring adopts a chair 239 
conformation (Figure 3, Figures S6-S8). The deacylating water, similarly positioned by 240 
Glu166 and Asn170 in all complexes, lies close to the C7 atom (see Figure 1 for atom 241 
numbering) of relebactam (2.9Å – 3.2Å), and is apparently positioned for decarbamylation 242 
(Figures S6-S8 panels B and D). Differences we observe between enzymes in koff (i.e. the 243 
decarbamylation rate of the ‘acyl’-complex) are therefore probably at least not solemnly due 244 
to changes in the position of the deacylating water. A second active site water molecule 245 
(Wat2), and its interactions with residues 237 and the N17 atom of relebactam, is also 246 
conserved across the 5 enzymes (Figure 6-8A and D). 247 
 248 
Comparisons of DBO Binding 249 
The efficacy of avibactam and extensive research into structure-activity relationships (SAR) 250 
has prompted the development of further generations of DBOs with modifications to the R1 251 
side chain, including relebactam. Comparisons of relebactam binding with other KPC-2, L2 252 
and CTX-M-15 DBO complexes reveal common modes of binding for the inhibitor core. The 253 
avibactam carboxyamide side chain in KPC-2 (PDB 4ZBE) adopts a similar geometry to the 254 
O16 and N17 atoms of relebactam with the only difference being the position of Wat2 255 
(Figure S10A). Despite this movement, Wat2 still hydrogen bonds to the N17 atom in both 256 
avibactam and relebactam complexes with KPC-2 (34). WCK-5107, also known as 257 
zidebactam, has a Ki against KPC-2 5-fold higher than avibactam and 2-fold higher than 258 
relebactam, but only differs from relebactam by an additional amine at position 18. In a KPC-259 
2 complex structure obtained after a 3 hour soak (PDB: 6B1J)(16) (Figure S10B) the 260 
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piperidine ring of WCK-5107 binds closer (by approximately 3.0 Å) to the backbone oxygen 261 
of Cys238 than that of relebactam. The disulfide bond that this residue forms with Cys69 is 262 
known to be important to the hydrolytic activity, including carbapenemase activity, of KPC 263 
enzymes (35, 36).  264 
 265 
In the co-crystal structure of the WCK-5107 complex (Figure S10C), a desulfated, imine 266 
form of the DBO is modelled, binding similarly to the imine conformation of relebactam 267 
observed here. WCK-4234, the most potent DBO described by Papp-Wallace et al (16), with 268 
cross-class activity against SBLs, binds to KPC-2 with its R1 side chain pointing toward 269 
Asn132, in contrast to the N17 of relebactam which points in the ‘opposite’ direction (Figure 270 
S10D). As with other DBOs, the N6, O10 and sulfate moiety of WCK-4234 are all flexible, 271 
and modelled in a range of different conformations compared with relebactam.  272 
 273 
In both CTX-M-15 and L2, DBO binding modes are similar, with only a small rotation of the 274 
R1 carboxyamide when comparing avibactam and relebactam (Figure S10E and S10F). In 275 
L2, this results in an additional water molecule, not present in the avibactam complex, that 276 
bridges N17 of relebactam (Wat2) with the Ser237 side chain oxygen. For each of the 277 
comparisons described above (Figure S10), the sulfate moiety and attached O10 atom adopt 278 
subtly different conformations in each of the complexes, particularly compared with 279 
relebactam. This observation implies flexibility in binding for this region of the DBOs, 280 
though numerous factors may underline the differences, including the different resolution 281 
limits for each crystal structure, soaking times, or crystallization conditions, and in the case 282 
of L2, additional interacting water molecules in the active site. 283 
 284 
Hydrogen Bonding of Relebactam in Class A Active Sites 285 
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Relebactam is positioned to form hydrogen bonds with the oxyanion hole (Ser70 and Thr237 286 
backbone amides), Asn132 and Ser130, residues that are all conserved (Figure 4) in the five 287 
enzymes. In the L2 and KPC-variants, the Thr216 backbone oxygen also partakes in 288 
hydrogen bond networks (via a water molecule, Wat3 in KPCs and Wat3-5 in L2, Figure 4), 289 
to the relebactam sulfate, an interaction absent in the CTX-M-15 complex. This is probably 290 
due to the flexible binding of the sulfate moiety, as described above. In addition, the L2 291 
structure contains two active site water molecules uniquely observed bridging relebactam and 292 
residues Tyr272, Arg244, Lys234 and Gly236 (Figure S6). These additional interactions in 293 
L2 and the KPCs may contribute to the smaller Ki values compared to CTX-M-15 (Table 3). 294 
 295 
Flexibility in Residues 104 (CTX-M-15) and 105 (L2, KPCs) is Important for 296 
Relebactam Binding.  297 
Residues 104 and 105 lie at the entrance of the active site in all class A β-lactamases. Residue 298 
105 has been investigated extensively in TEM-1 (37, 38), SME-1 (35) and KPC-2 (39) and is 299 
thought to have important roles in discriminating between, and stabilizing bound, substrates/ 300 
intermediates during hydrolysis (Figure S3). In the structure of unliganded KPC-2 (PDB 301 
5ul8), Trp105 has poorly defined electron density, suggestive of the presence conformational 302 
flexibility (40). Indeed, this is also the case in our unliganded KPC-3 and KPC-4 structures, 303 
solved in the same space group (P21212), where Trp105 is modelled in two conformations 304 
(Figure S3). This movement has only been observed in KPC-2 crystal structures solved in 305 
the space groups P21212 or P22121. In other KPC-2 crystal structures solved in different space 306 
groups, e.g. 3DW0 (41) and 2OV5 (42), the Trp105-containing loop is stabilized by crystal 307 
contacts and Trp105 movement is not observed. In crystal structures of the hydrolysis 308 
products of cefotaxime and faropenem non-covalently bound to KPC-2 (40) (space group 309 
P22121), Trp105 is modelled in one conformation into clear electron density, revealing that 310 
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substrate and/or product binding stabilizes the conformation of this residue. However, in the 311 
KPC-2:relebactam complex, both Trp105 and the relebactam piperidine ring are modelled in 312 
two conformations (Figure 3, Figure 4D and Figure S7A).  313 
 314 
In KPC-3 and -4 relebactam complexes Trp105 is modelled in one conformation, similar to 315 
one of the two conformations observed in KPC-2, albeit with high B-factors (30.95 and 33.19 316 
compared to average protein B-factors of 13.61 and 13.24, respectively) suggesting there is 317 
still flexibility and movement of this residue. In this conformation Trp105 faces the DBO 318 
core, with the nitrogen of the pyrrole ring ~3.0 Å from the relebactam imine N6. This is 319 
concomitant with well-defined electron density for the relebactam piperidine ring (Figure 3). 320 
Therefore, movement of Trp105 and binding of the piperidine ring appear linked, with 321 
potential for steric clashes to occur if Trp105 were positioned to face the C2 side chain. 322 
While the flexibility of this residue may be allowing the KPC-2 active site to accommodate 323 
relebactam, the necessity of rearrangement to avoid these steric clashes likely contributes to 324 
the decrease in potency of relebactam compared with avibactam.  325 
 326 
In the CTX-M-15:relebactam complex, unlike the other SBLs studied here, electron density, 327 
for both Asn104 and the relebactam piperidine ring is poorly defined. In crystal structures of 328 
wildtype CTX-M enzymes Asn104 is well defined by experimental electron density but is 329 
positioned to clash sterically with the expected orientation of the piperidine ring of bound 330 
relebactam (Figure 3 and S9). Thus, relebactam binding appears to increase the 331 
conformational flexibility of CTX-M-15 Asn104 in order to escape such unfavorable 332 
interactions. We propose that the need to reposition Asn104 on relebactam binding 333 
contributes to the slower carbamylation-rate and higher Kiapp (Table 3) for CTX-M-15, 334 
compared to the other enzymes tested here. 335 
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 336 
In L2, two conformations of His105 are observed on relebactam binding, with one 337 
configuration the same as that observed in the L2:avibactam and native structures, which 338 
each contain a single His105 conformation. As in CTX-M-15, these movements are not 339 
observed in unliganded enzyme, or in the avibactam-bound L2 structure (25). These 340 
energetically unfavorable clashes may indicate why relebactam is 30-fold worse than 341 
avibactam at inhibiting L2 (Table 2).  342 
 343 
With these observations in mind, it is noteworthy that, of DBO compounds tested to date, the 344 
compound with the shortest R1-group, WCK-4234, exhibits the greatest potency (Ki) against 345 
KPC-2. This may be explained by comparisons of the crystal structures of KPC-2 complexed 346 
with WCK-4234 and relebactam (Figure S10D); notably, the nitrile R-group of bound WCK-347 
4234 points away from Trp105, whereas the relebactam (piperidine-containing) R-group 348 
adopts multiple conformations, of which some clash with Trp105. 349 
 350 
Crystal Structures of SBL:Relebactam Complexes Reflect Two Potential Pathways for 351 
Relebactam Release 352 
Two pathways for avibactam release (Figure S11) are postulated to occur, decarbamylation 353 
after DBO recyclization or decarbamylation by direct hydrolysis after loss of the inhibitor 354 
sulphate. First, Ehmann et al observed, in experiments monitoring transfer of the acylating 355 
group between the class A enzymes TEM-1 and CTX-M-15, that decarbamylationoccurs 356 
predominantly through regeneration of intact avibactam (i.e. recyclization) (13). Second, in 357 
complexes with KPC-2 the avibactam ‘acyl’-enzyme can slowly hydrolyze without 358 
recyclization, with the observation that only 10% of KPC-2 remains acylated after 24 hours 359 
incubation suggestive of a slow, hydrolytic mechanism (20). In time-course experiments 360 
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monitoring the stability of the KPC-2:avibactam ‘acyl’-enzyme two new ‘acyl’-enzyme peaks 361 
were identified by MS indicating losses of 79 and 98 Da, consistent with loss of SO4
2-
362 
(desulfation) with formation of either hydroxylamine or imine fragments (Figure S11). It is 363 
thought that these fragmentations precede avibactam loss by hydrolysis and result in relief of 364 
inhibition as the released fragments are incapable of forming intact DBO by recyclization. 365 
 366 
We therefore examined our various relebactam complex crystal structures with the aim of 367 
establishing their compatibility with these competing pathways for loss of covalent 368 
attachment from the enzyme. In the CTX-M-15 complex electron density indicates that 369 
bound relebactam is in two clear conformations, with occupancies of 0.51 and 0.49 (Figure 370 
3A). In one of these two conformations, the relebactam N6 atom interacts closely (2.9 Å) 371 
with Ser130, leaving N6 closer to the carbamoyl group than Wat1, and resembling the 372 
recyclization ‘primed’ state previously reported for class A SBLs12 (PDB:4HBU) (Figure 373 
S6D). Additionally, short hydrogen bond distances (2.9 Å) are observed between Lys73 and 374 
Ser130, similar to those found in the avibactam crystal structure (PDB: 4S2I). Lys73 has been 375 
proposed to act as a general base for Ser130 activation for avibactam recyclization(19); the 376 
crystal structure of CTX-M-15:relebactam presented here identifies that this is likely also the 377 
case for relebactam. This “recyclization primed” conformation for class A enzyme-bound 378 
DBOs has only been previously observed in the CTX-M-15:avibactam (19) and the KPC-379 
2:WCK-4234 complexes(16) (Figure S10). However, we also note the presence of a second 380 
conformation of relebactam in CTX-M-15 that closely resembles that found in avibactam 381 
complexes of other enzymes, with N6 positioned further from Ser130 (3.5-4.1 Å) and C7 382 
(Figure S6, S7 and S8 C+F) i.e. not primed for recyclization (Figure S6D, E+F). The 383 
presence of these alternative conformations seems to have little impact on DBO off-rates, 384 
with previous studies determining off rates of 1.4 - 6.7 × 10
-4
 s
-1
 for avibactam from CTX-M-385 
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15 (20, 43, 44) and 4.5 ± 0.5 × 10
−4
 s
-1
 for WCK-4234 (16) from KPC-2, similar to the 386 
relebactam off-rates observed here (Table 3). 387 
 388 
In the complex with L2, which contains intact (i.e. non-desulfated, but ring-opened) 389 
relebactam in a single conformation, Lys73 and Ser130 were similarly close to one another 390 
(Figure 5). Despite this proximity, Ser130 is ~ 3.9 Å away from the N6 nitrogen, and so 391 
relebactam appears to be still not primed for recyclization in L2. However, in each of the 392 
three KPC complexes, in all of which relebactam was a modelled as a mixture of intact and 393 
desulfated forms, Lys73 is at least 0.4 Å more distant from Ser130, than is the case for either 394 
the CTX-M-15 (either conformation) or L2 structures. These increased distances, when 395 
considered with the postulated recyclization pathway that involves proton transfer from 396 
Ser130 to Lys73, in addition to the distance of at least 3.5 Å between Ser130 and the N6 of 397 
relebactam, suggest that recyclization is less favorable in the KPC complexes than in those 398 
formed with the other two enzymes. 399 
 400 
Consistent with this possibility, in the KPC-2, KPC-3 and KPC-4 structures, inspection of 401 
electron density maps indicated the presence of desulfated relebactam, which could be 402 
modelled as the imine form of the inhibitor, with occupancies of 0.35, 0.33 and 0.65 for 403 
KPC-2, -3 and -4, respectively. The imine group points towards the flexible Trp105, but 404 
otherwise the DBO core closely resembles intact relebactam.  405 
 406 
It had previously been thought that relebactam complexes with class A SBLs did not undergo 407 
desulfation, with mass spectrometry experiments with KPC-2 suggesting that fragmentation 408 
was not occurring even after 24 hours’ incubation (16, 21). However, our KPC complex 409 
structures provide crystallographic evidence supporting potential relebactam desulfation, at 410 
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least in crystallo, after 16 hours’ incubation. To further investigate the possibility of 411 
relebactam desulfation, LC-ESI MS studies were carried out on the full-length (codons 25-412 
293) proteins at a range of time points after exposure to both avibactam and relebactam. All 413 
KPC variants tested manifested apparently complete carbamylation, without significant 414 
fragmentation, by both DBOs within 5 min, in agreement with the fast on-rates we observe 415 
kinetically. Initially, acquired spectra showed only adducts of + 265 Da and + 348 Da, 416 
respectively, indicating carbamylation of intact avibactam and relebactam, respectively. Over 417 
a period of 37 h gradual fragmentation of the complexes to adducts with masses decreased by 418 
80 Da and 98 Da (forming the hydroxylamine and imine species, respectively), compared to 419 
the initial ‘acyl’-enzyme complexes, was observed by the mass spectrometric method 420 
employed here. This is in agreement with fragmentation of the initially formed enzyme-421 
inhibitor complexes as described by Ehmann et al (13, 20). For all KPC variants tested 422 
fragmentation of the avibactam-complex was faster than that of the relebactam-complex, with 423 
desulfated avibactam adducts more evident in spectra after 4h incubation and accumulating to 424 
higher levels over the duration of the experiment. This slow rate of relebactam desulfation is 425 
consistent with the in crystallo observations, with relebactam appearing to remain fully 426 
sulfated in KPC-4 crystals soaked for 1 hr (Figure 3C, Figure S8D, E and F). This complex 427 
shows no large differences compared to that obtained after a 16-hour soak (Figure 3F, 428 
Figure S8 A, B and C) with the piperidine ring well defined (Figure 3C) and only small 429 
changes in the positions of N6, O10 and the sulfate moiety, compared to the other relebactam 430 
complexes (Figure 4). Additional MS experiments however at pH values ranging from 7.0 – 431 
8.5 revealed a significant pH dependence of desulfation, which was enhanced in a basic 432 
environment. We note that in crystals soaked in acidic conditions (pH 4-5) no desulfation was 433 
observed for other DBOs after 3-hours, yet did occur in longer (~3 days), co-crystallization 434 
experiments at the same pH (16). 435 
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 436 
These data provide clear evidence that, whilst relebactam:KPC ‘acyl’-enzymes can undergo 437 
limited desulfation, with the enzymes tested here this occurs much more slowly than for 438 
avibactam. It has been previously been suggested, based upon in silico docking relebactam 439 
into the KPC-2 active site, followed by molecular dynamics simulations, that movements of 440 
water molecules away from the sulfate moiety (compared to their positions in avibactam 441 
complexes) increase the stability to desulfation of relebactam (21). However, even though we 442 
observe a lower rate of relebactam desulfation compared to avibactam, our KPC-2, -3 and -4 443 
crystal structures (determined at higher resolution than the previous KPC-2:avibactam 444 
complex(34)) all contain an additional active site water molecule (Wat4, Figure 4) close to 445 
the relebactam sulfate group that is not present in the avibactam complex. Thus, the reason 446 
for the increased stability of relebactam, and the mechanism by which the nature of the R1 447 
side chain on the DBO core structure affects the desulfation rate, remains uncertain. 448 
 449 
Conclusions 450 
Diazabicyclooctanes are an emerging and evolving class of BLIs, with the core scaffold 451 
capable of accepting modifications at the C2 position that allow further iterations to improve 452 
efficacy. Here, we demonstrate that relebactam, the most recent DBO to enter phase 3 clinical 453 
trials, inhibits diverse, clinically-relevant class A SBLs: L2, CTX-M-15, and three KPC 454 
variants, albeit at reduced potency compared to avibactam. This reduction in potency in vitro 455 
is not enough to impair the effectiveness of relebactam combinations against relatively 456 
permeable K. pneumoniae Ecl8 yet does impact efficacy against other organisms. Indeed, 457 
compared to the aztreonam:avibactam combination currently being developed for clinical 458 
use, an aztreonam:relebactam combination showed decreased efficacy against S. maltophilia 459 
K279a, indicating likely limitations in the effectiveness of relebactam combinations against 460 
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less permeable pathogens. This is consistent with a previous report that relebactam:imipenem 461 
combinations are ineffective against A. baumanii (14). 462 
 463 
Our structural data show unfavorable clashes of the relebactam piperidine ring with -464 
lactamase residues 104 (CTX-M-15) and 105 (L2 and KPCs) that may explain differences in 465 
potency between DBOs. Indeed, the DBO compound WCK-4234, which contains the shortest 466 
R1 side chain of those tested to date, displays the greatest potency against class A SBLs, as 467 
well as, surprisingly, inhibiting a class D enzyme, OXA-48, with a Ki of 0.29 µM, which 468 
compares favorably with values of 30 µM for avibactam and >100 µM for relebactam (16). In 469 
addition, DBOs with modifications at the C3 and C4 positions, yet small C2 modifications, 470 
also show promising potency across SBL classes, with several compounds, for example 471 
ETX2514, exhibiting nanomolar inhibition in IC50 assays (17). Our crystal structures also 472 
highlight that, compared to avibactam, relebactam makes fewer interactions in the CTX-M-473 
15 complex, which likely contributes to a reduction in potency against this enzyme. Our 474 
observations also provide evidence that the relebactam:KPC carbamylated enzyme complex 475 
can desulfate, albeit more slowly than that formed with avibactam. These data indicate that 476 
the identity of the R1 (C2) side chain of DBOs can influence desulfation, although the 477 
underlying mechanism remains to be elucidated. As desulfation prevents recyclization of the 478 
inhibitor, leading ultimately to release of inactive degradation products and recovery of active 479 
enzyme, this could affect the potency and longevity of the inhibitor. Whilst the timescale of 480 
relebactam desulfation that we observe here is noticeably slower than that for avibactam, 481 
likely limiting the immediate clinical relevance of this mechanism, its existence raises the 482 
possibility that KPC variants capable of supporting faster desulfation may emerge under 483 
selection pressure imposed by DBO use. For these reasons the mechanism and determinants 484 
of DBO desulfation by different class A β-lactamases deserve more detailed investigation. 485 
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 486 
The DBO scaffold and current derivations are extremely important additions to the 487 
therapeutic arsenal against resistant Gram-negative pathogens. Nevertheless, differences 488 
between individual DBOs in potency towards specific enzymes can impact the efficacy of 489 
treating problematic β-lactamase producing pathogens, especially “difficult” organisms such 490 
as S. maltophilia. Our extensive comparisons highlight these differences, and provide 491 
significant insights that may guide further development of the core DBO inhibitor scaffold, in 492 
particular by emphasising the need to consider the possible impact of C2 substitution on 493 
susceptibility of the carbamylated KPC complex to degradation as well as upon interactions 494 
with the -lactamase active site.  495 
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Materials and Methods 496 
 497 
Minimum Inhibitory Concentration Determination 498 
The pUBYT vector containing blaKPC-3 under the ISKpn7 promoter was used as a template for 499 
site-directed mutagenesis to create pUBYT containing blaKPC-2 and blaKPC-4 with the same 500 
promoter (45). The single point mutation in KPC-2 (Y274H) and double point mutations in 501 
KPC-4 (P104R, V240G) were introduced using QuikChange Lightening site-directed 502 
mutagenesis kit (Agilent Genomics) with the primers specified in Table S1. Klebsiella 503 
pneumoniae Ecl8 was transformed with the resulting pUBYT constructs via electroporation. 504 
S. maltophilia K279a is a well-characterized isolate from Bristol, UK, and was obtained as 505 
previously reported (46).  506 
 507 
MIC values were determined using broth microdilution, in triplicate, in cation-adjusted 508 
Mueller Hinton broth (Sigma) according to the Clinical Laboratory Standards Institute 509 
(CLSI) guidelines (47). Experiments were performed in microtiter plates (Corning) 510 
containing medium with ceftazidime, imipenem or aztreonam with inhibitor (4 mg.L
-1
 511 
avibactam (MedChemExpress) or relebactam (MedChemExpress) dissolved in dimethyl 512 
sulfoxide). Plates were incubated overnight at 37 °C for 18–24 h, and the absorbance at 600 513 
nm was read using a POLARstar Omega (BMG LabTech) plate reader.  514 
 515 
Protein Purification and Crystallization 516 
The L2 β-lactamase was purified and crystallized as described previously (25). The mature 517 
polypeptide (codons 28-290) of CTX-M-15 in the expression vector pOPINF (48) was 518 
expressed in SoluBL21 (DE3) E. coli cells (Genlantis) and grown in 2xYT medium 519 
supplemented with 50 µg/mL carbenicillin to produce N-terminally His-tagged CTX-M-15. 3 520 
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litres of culture were incubated at 37°C until reaching an OD600 of 0.8 and subsequently 521 
grown at 18°C overnight with 0.75 mM IPTG to induce protein expression. Cells were 522 
harvested by centrifugation (6,500 × g, 10 min) and resuspended in 100 mL of 50 mM 523 
HEPES pH 7.5, 400 mM NaCl (Buffer A) with Complete EDTA-free protease inhibitor 524 
(Roche), 2 μl Benzonase® Endonuclease and lysozyme (Sigma). Homogenized cells were 525 
lysed with 2 passages through a cell disruptor (25 kpsi) and pelleted at 100,000 × g, 1 h. 526 
Following addition of 10 mM imidazole the supernatant was incubated with 4 mL of Ni-NTA 527 
resin (Qiagen) for 1.5 hours. Protein-bound resin was washed in 80 mL of Buffer A plus 528 
10 mM imidazole followed by 40mL of Buffer A plus 20 mM imidazole. Protein was eluted 529 
with Buffer A plus 400mM imidazole and concentrated in an Amicon 10-kDa molecular 530 
weight cut off (MWCO) centrifugal filter. The imidazole concentration was reduced to 531 
10 mM before addition of 3C protease overnight at 4 °C to remove the N-terminal His-tag. 532 
Cleaved tags were captured on Ni-NTA resin following incubation for 1 hour. CTX-M-15 533 
was loaded onto a Superdex S75 column (GE Healthcare) equilibrated with 50mM HEPES 534 
7.5 150mM NaCl and peak fractions analyzed by SDS-PAGE. Fractions assessed as >95% 535 
pure were pooled and concentrated to 37 mg.mL
-1 
using an Amicon 10-kDa MWCO 536 
centrifugal filter. CTX-M-15 was crystallized using sitting-drop vapor diffusion in 537 
CrysChem24 well plates (Hampton Research) at 20°C based on a method previously 538 
described (19). Drops comprised 1 µL of protein (15-37 mg/mL) and 1 µL of crystallization 539 
reagent (0.1M Tris pH 8.0 and 2.4 M ammonium sulphate) and were equilibrated against 500 540 
µL reagent.  541 
 542 
For the KPC variants (KPC-2, KPC-3 and KPC-4) codons 25-293 were cloned into pET28a 543 
(Noavagen) and expressed in E. coli BL21(DE3) (Novagen). Cells harboring the KPC 544 
expression vectors were grown in Auto induction media (Formedium) supplemented with 50 545 
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µg/mL kanamycin at 37°C for 8 hours, then at 18°C for 16 hours. Cells were harvested by 546 
centrifugation (6,500 × g, 10 min), then resuspended in 40 mL of 20 mM Tris pH 8.0, 300 547 
mM NaCl (Buffer B) with a complete EDTA-free protease inhibitor (Roche), 2 μl 548 
Benzonase® Endonuclease and lysozyme. Homogenized cells were lysed with 2 passages 549 
through a cell disruptor (25 kpsi), then pelleted (100,000 × g, 1 h). Following addition of 550 
10 mM imidazole the supernatant was loaded on to a 5 mL His-trap™ column (GE 551 
Healthcare) equilibrated with Buffer B. His-tagged protein was eluted by a linear imidazole 552 
gradient (20-300 mM) and fractions analyzed by SDS PAGE. Fractions containing KPC were 553 
pooled and loaded onto a Superdex S75 column equilibrated with Buffer B and peak fractions 554 
analysed by SDS-PAGE. Fractions assessed as >95% pure were pooled and concentrated to 555 
16.3 mg.mL
-1 
KPC-2, 18.2 mg.mL
-1 
KPC-3 and 14.5 mg.mL
-1 
KPC-4
 
using an Amicon 10-556 
kDa MWCO centrifugal filter.  557 
 558 
KPC-2 was crystallized using sitting-drop vapor diffusion in CrysChem24 well plates 559 
(Hampton Research) at 20°C based upon previously described conditions (40). Drops 560 
comprised 2 µL of protein (16.3 mg.mL
-1
) and 1 µL of crystallisation reagent (2.0 M 561 
ammonium sulphate and 5% v/v ethanol) and were equilibrated against 500 µL of reagent. 562 
Initial crystals were optimized by seeding with a Seed Bead™ Kit (Hampton research). Drops 563 
comprised 2 µL of protein (16.3 mg.mL
-1
), 1 µL crystal seed and 1 µL of crystallisation 564 
reagent and were equilibrated against 500 µL reagent. KPC-3 and KPC-4 crystals were 565 
grown using the same conditions, using the KPC-2 crystal seed.  566 
 567 
Inhibitor Soaking, Data Collection and Structure Determination. 568 
Crystals of L2, CTX-M-15, KPC-2, KPC-3 and KPC-4 were soaked in mother liquor 569 
supplemented with 1 mM relebactam. Crystals were then briefly exposed to mother liquor 570 
 o
n
 Septem
ber 13, 2019 at University of Bristol Inform
ation Services
http://aac.asm
.org/
D
ow
nloaded from
 
containing 30% glycerol and flash-frozen in liquid nitrogen. Diffraction data for native and 571 
inhibitor-soaked crystals were collected at Diamond Light Source on beamlines I03 (L2 and 572 
CTX-M), I04 (KPC-3 and KPC-4) and I24 (KPC-2). Images were indexed and integrated 573 
using Dials (49) in the Xia2 (50) pipeline at Diamond Light Source and subsequently scaled 574 
in aimless (CCP4 suite (51)). Data were phased by molecular replacement in Phaser (52) 575 
(CCP4 suite (51)) with 5NE2 (25) (L2), 4HBT (19) (CTX-M-15) and 5UL8 (40) (KPCs) as 576 
the starting structures. Initial refinement in Refmac (53) (CCP4 suite (51)) confirmed Fo-Fc 577 
electron density consistent with bound ligand, prior to further rounds of refinement in 578 
phenix.refine (54) and manual model building in WinCoot (55). Geometry restrains for 579 
relebactam were calculated using eLBOW and omit maps were generated in Phenix (54) from 580 
the final model in absence of the ligand. Figures were generated in Pymol (56). 581 
 582 
Enzyme Assays. 583 
All enzyme assays were performed at 25 °C in 10 mM HEPES pH 7.5, 150 mM NaCl, with 584 
nitrocefin hydrolysis followed at 486 nm (57) (Δε 486 = 20,500 M-1.cm-1) using Greiner half 585 
area 96-well plates and a Tecan Infinite 200 Pro microplate reader. Kinetic parameters were 586 
calculated and analyzed using GraphPad Prism 6. Steady-state parameters kcat and KM for 587 
nitrocefin hydrolysis were calculated by measuring initial rates of nitrocefin hydrolysis with 588 
L2 (1 nM), CTX-M-15 (1 nM), KPC-2 (10 nM), KPC-3 (10 nM) or KPC-4 (10 nM) and 589 
plotted against nitrocefin concentration. Steady-state values are provided in Table S2. 590 
 591 
IC50 values were determined by following the initial rates of nitrocefin hydrolysis (50 µM) 592 
measured after 10-minute pre-incubation of inhibitor and enzyme (conditions as established 593 
by Cahill et al (48)). Diazabicyclooctanes were dissolved in DMSO (100 mM) and diluted to 594 
the desired concentration in 10 mM HEPES pH 7.5, 150 mM NaCl. Reactions were initiated 595 
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by addition of nitrocefin, and initial rates plotted against log10[diazabicyclooctane] and fitted 596 
to Equation 1. Data were fitted to a four-parameter variable slope to obtain IC50 values. 597 
Equation 1.  598 
 599 
 600 
Y is the observed rate, [I] is inhibitor concentration and s the concentration of substrate 601 
(nitrocefin). 602 
 603 
The interaction between relebactam (I) and the five enzymes (E) was investigated using 604 
kinetic models described previously (Scheme 1 (13, 17, 20, 43, 58-60)). For DBO inhibitors, 605 
interactions with SBLs may be described by two major pathways respectively involving 606 
reversible formation of a covalent carbamylated complex (Scheme 1 E-I, whose 607 
decarbamylation yields active enzyme and intact inhibitor), and fragmentation of bound 608 
inhibitor via desulfation and hydrolysis to liberate active enzyme and non-inhibitory species 609 
(20) (Figure 5). 610 
Scheme 1: 611 
Formation of the non-covalent (Michaelis) complex E:I is described by the equilibrium 612 
constant K, equivalent to k-1/k1 (reverse and forward rate constants, respectively). k2 is the 613 
first-order rate constant for carbamylation, or formation of E-I. k-2 is the first-order rate 614 
constant for the recyclization step (decarbamylation; reformation of E:I). Formation of 615 
Y=
100
(1+10((LogIC50-[I])∗𝑠) )
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covalent imine and desulfated complexes collectively described as E-I’ is described by k3, 616 
and release of (inactive) inhibitor degradation product(s) P by k4. 617 
 618 
Fragmentation of the carbamylated relebactam complex occurs at low levels and was only 619 
detected after 4 hours’ incubation of enzyme and inhibitor (Figure 5 C, E and G). 620 
Accordingly, within the time frame of initial velocity experiments described here, Scheme 1 621 
can be simplified to Scheme 2 as used to describe slow-binding reversible enzyme inhibition 622 
(61). 623 
Scheme 2: 624 
 625 
 626 
Where k1 and k-1 represent the association and dissociation rate constants for formation of the 627 
non-covalent complex described by K, and k2 and k-2 the carbamylation and decarbamylation 628 
(recyclization) rate constants, respectively. 629 
 630 
The apparent inhibition constant Kiapp (Scheme 2; (16, 21, 33, 62-65)) and second-order rate 631 
constant for the onset of carbamylation by relebactam k2/K (see also (13, 17, 20, 43, 58-60)) 632 
across all enzymes were determined through direct competition assays of relebactam and 633 
nitrocefin under steady-state conditions. Nitrocefin was used at a fixed concentration of 50 634 
µM; enzyme concentrations used were 1 nM (L2), 2 nM (CTX-M-15) or 10 nM (KPC-2, 635 
KPC-3 and KPC-4). Kiapp’ (uncorrected value for Kiapp) was then determined from Dixon 636 
plots (32) (of the initial rates (v0) of nitrocefin hydrolysis (µM/sec) measured in the presence 637 
of increasing concentrations of relebactam without pre-incubation. The reciprocals of these 638 
initial rates (1/v0) were plotted against relebactam concentration [I], giving a straight line for 639 
which the value of the intercept divided by the slope gives Kiapp’. These data were corrected 640 
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to account for the KM for nitrocefin (KM(NCF), as determined experimentally, data in Table S2) 641 
using Equation 2 to generate values for Kiapp. 642 
Equation 2. 643 
 644 
 645 
where [S] is the concentration of nitrocefin. 646 
 647 
The experiments monitoring nitrocefin hydrolysis in the presence of differing relebactam 648 
concentrations were also used to obtain values for k2/K (apparent second-order rate constant 649 
for the onset of carbamylation). Complete progress curves were fitted to Equation 3 in order 650 
to obtain values for kobs (pseudo-first-order rate constant for inactivation).  651 
Equation 3. 652 
 653 
 654 
Where A is absorbance at 486 nm measured at time t, v0 and vf are the initial and final 655 
velocities and A0 the initial absorbance at 486 nm. 656 
 657 
The apparent second order rate constant k2/K was then obtained by plotting kobs against 658 
[relebactam] ([I]) according to Equation 4, with k2/K’ (uncorrected value for k2/K) then equal 659 
to the slope of the line.  660 
Equation 4. 661 
 662 
 663 
The value obtained for k2/K’ was then corrected using KM values for nitrocefin (KM(NCF), as 664 
determined experimentally, Table S2) in Equation 5 (where [S] is nitrocefin concentration) 665 
𝐾𝑖𝑎𝑝𝑝  = 𝐾𝑖𝑎𝑝𝑝′ /1 + (
[𝑆]
K
M(NCF)
) 
k
obs
= k-2 + k2/𝐾′ ∗  [𝐼] 
A = vf  ∗  t  + (v0 - vf )∗ ((1 − 𝑒 
-kobs * t)/k
obs
) + A0 
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to yield k2/K. (Note that, although the quality of our straight-line fits for kobs against 666 
[relebactam] is good, the fact that these experiments (along with others’ (21, 33)) necessitated 667 
use of relebactam at concentrations approaching Kiapp may introduce some uncertainty into 668 
values for k2/K.) 669 
Equation 5.  670 
 671 
 672 
 673 
To determine the rate of recovery of free enzyme, koff, 1 µM enzyme was incubated with 17.5 674 
µM relebactam in kinetics buffer (50 mM HEPES pH7.5, 150 mM NaCl) for 10 minutes at 675 
room temperature. This mixture was serially diluted and reaction was then assayed by 676 
addition of nitrocefin to a final concentration of 50 µM, final enzyme concentrations were as 677 
follows: 50 nM KPC-2, 5 nM KPC-3, 50 nM KPC-4, 50 pM CTX-M-15 and 50 pM L2. 678 
Complete progress curves were collected, and the results fitted to Equation 6 to obtain koff . 679 
Equation 6. 680 
 681 
 682 
Where A is absorbance at 486 nm measured at time t, v0 and vf are the initial and final 683 
velocities and A0 the initial absorbance at 486 nm. 684 
 685 
Mass Spectrometry of Relebactam Fragmentation in KPC Variants.  686 
To investigate modifications to the KPC enzymes by avibactam and relebactam, 3 μM 687 
enzyme in 50 mM Tris-HCl pH 7.5 (unless stated otherwise) was incubated with 6 μM 688 
avibactam or relebactam at room temperature. Mass spectra were acquired in the positive ion 689 
mode using an integrated autosampler/solid phase extraction (SPE) RapidFire365 system 690 
A = vf  ∗  t  + (v0- vf ) ∗ (1 − 𝑒
-koff t )/ koff + A0 
k2/K = k2/K ' ∗ ((
[𝑆]
K
M(NCF)
) + 1) 
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(Agilent Technologies) coupled to an Agilent 6550 Accurate Mass QTOF mass spectrometer. 691 
After the indicated time 50 μl of sample was loaded onto a C4 SPE cartridge (Agilent 692 
Technologies), washed with buffer D (100% (v/v) water, 0.1% (v/v) formic acid) and 693 
subsequently eluted to the mass spectrometer in buffer E (15% (v/v) water, 85% (v/v) 694 
acetonitrile, 0.1% (v/v) formic acid). The cartridge was re-equilibrated in buffer D in between 695 
samples. Data were analyzed using MassHunter Qualitative Analysis software V.7 (Agilent 696 
Technologies) using the maximum entropy deconvolution algorithm.  697 
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 932 
Table 1. Minimal Inhibitory Concentrations of β-lactams Against S. maltophilia or K. 
pneumoniae in the Presence of β-lactamase Inhibitors. 
 Ceftazidime Imipenem Aztreonam 
 - +AVI (4 
mg/L) 
- +REL (4 
mg/L) 
- +REL (4 
mg/L) 
S. maltophilia 
K279a 
16 8 128 64 >256 8 
Ecl8 pUBYT  <0.125 - <0.0625 - - - 
Ecl8 pUBYT 
KPC-2 
16 0.125 64 0.5 - - 
Ecl8 pUBYT 
KPC-3 
128 <0.125 16 <0.125 - - 
Ecl8 pUBYT 
KPC-4 
128 1 0.5 0.125 - - 
 AVI, avibactam; REL, relebactam 
 933 
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Table 2. IC50 Values for DBO Inhibitors Against Class A β-Lactamases. 
Protein Avibactam (nM) Relebactam (nM) 
CTX-M-15 3.4 (0.02) 400 (0.04) 
L2 15 (0.02) 470 (0.03) 
KPC-2 10 (0.05) 230 (0.03) 
KPC-3 29 (0.03) 260 (0.05) 
KPC-4 9.3 (0.08) 910 (0.03) 
Standard error of log IC50 values are shown in parentheses. 
 935 
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Table 3. Kinetic Parameters for Relebactam Inhibition.  
 Kiapp  (µM) k2/ K (M
-1
 s
-1
) koff (s
-1
) t ½ (min) 
L2 
2.7  
(0.7) 
4000  
(620) 
0.00055 
(0.000021) 
21 
CTX-M-15 
21.0  
(1.0) 
540 
(19) 
0.00038 
(0.000053) 
30 
KPC-2 
1.2  
(0.05) 
4500 
(220) 
0.00087 
(0.000032) 
13 
KPC-3 
1.5  
(0.05) 
2100 
(140) 
0.00020 
(0.000035) 
58 
KPC-4 
4.8  
(0.7) 
1100 
(190) 
0.00019 
(0.000038) 
61 
Errors in parentheses represent standard deviation (Kiapp  and k2/ K) or 
standard error from fits of (koff) from measurements carried out in 
triplicate. 
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Table 4: Observed and Calculated Masses of KPC Variants Before and After 939 
Modification due to DBO Treatment. All differences between measured and expected 940 
masses are within experimental error. 
a
Masses implied from maximum entropy deconvolution 941 
of measured spectra. 
b
Masses were calculated based on protein sequences without an N-942 
terminal methionine. 
c
Corresponding to the observed protein masses. 
d’Acyl’ denotes a mass 943 
shift corresponding to reaction of an intact DBO molecule. 944 
 Mass(es) 
observed
a
 
[Da] 
Mass  
calculated
b
 
[Da] 
Mass 
shift(s) 
observed
c
 
[Da] 
Mass shift 
calculated 
[Da] 
Assignment
d*
 
KPC2  30640 30640    
 + avibactam 30905 30905 + 265 + 265 ‘acyl’ 
  30826 30825 + 186 + 185 ‘acyl’ – 80 
  30808 30807 + 168 + 167 ‘acyl’ – 98 
 + 
relebactam 
30989 30988 + 349 + 348 ‘acyl’ 
  30907 30908 + 267 + 268 ‘acyl’ – 80 
  30890 30890 + 250 + 250 ‘acyl’ – 98 
KPC3  30665 30667    
 + avibactam 30931 30932 + 266 + 265 ‘acyl’ 
  30851 30852 + 186 + 185 ‘acyl’ – 80 
  30834 30834 + 167 + 167 ‘acyl’ – 98 
 + 
relebactam 
31013 31015 + 348 + 348 ‘acyl’ 
  30935 30935 + 270 + 268 ‘acyl’ – 80 
  30914 30917 + 249 + 250 ‘acyl’ – 98 
KPC4  30657 30657    
 + avibactam 30922 30922 + 265 + 265 ‘acyl’ 
  30841 30842 + 184 + 185 ‘acyl’ – 80 
  30824 30824 + 167 + 167 ‘acyl’ – 98 
 + 
relebactam 
31005 31005 + 348 + 348 ‘acyl’ 
  30924 30925 + 267 + 268 ‘acyl’ – 80 
  30908 30907 + 251 + 250 ‘acyl’ – 98 
*A chemical scheme depicting the assigned  ‘acyl’, ‘acyl’ -80 and ‘acyl’ -98 species is 945 
displayed in Figure 5A.  946 
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 948 
 949 
Figure 1. Structures of the Diazabicyclooctanes (DBOs) Avibactam and Relebactam. 950 
 951 
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 953 
 954 
Figure 2. Kinetic Characterization of Relebactam Inhibition of KPC-2. (A) Dixon plot of 955 
reciprocals of initial nitrocefin hydrolysis rates (1/V) by enzyme:relebactam mixtures plotted 956 
against relebactam concentration. The apparent inhibition constant Kiapp is obtained from the 957 
slope of the fitted straight line. (B) Initial rates of nitrocefin hydrolysis (absorbance 958 
units/min) after 10-minute incubation with relebactam, plotted against log10 [relebactam]. 959 
Fitted curve is used to derive IC50 according to Equation 1. (C) Plot of kobs (pseudo-first-order 960 
rate constant for inactivation) against relebactam concentration. The apparent second-order 961 
rate constant for the onset of carbamylation k2/K is obtained from the slope of the fitted 962 
straight line. (D) Progress curve representing recovery of nitrocefin hydrolysis following 10 963 
minute pre-incubation of enzyme (1 µM) with 17.5 µM relebactam, diluted to a final 964 
concentration of 50 nM enzyme. The rate of recovery of free enzyme, koff, is obtained from 965 
the fitted line shown according to Equation 6. Data points shown are means of three replicate 966 
runs.  967 
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 968 
Figure 3. Electron Density Maps Showing Relebactam Bound to the Active Sites of 969 
Class A β-Lactamases. Unbiased omit Fo-Fc electron density maps were calculated with the 970 
ligand removed and are shown contoured at 3σ. Gray density is calculated after removal of 971 
‘intact’ relebactam, green density after removal of desulfated relebactam. (A) CTX-M-15 972 
(green, 16-hour soak); (B) L2 (teal, 16 hours); (C) KPC-4 (pink, 1 hour); (D) KPC-2 (yellow, 973 
16 hours); (E) KPC-3 (orange, 16 hours); (F) KPC-4 (16 hours). 974 
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Figure 4. Interactions of Relebactam with Active Sites of Class A β-Lactamases. Close-976 
up views of relebactam bound in the active sites of class A β-lactamases (colored as in 977 
Figure 3). Hydrogen bonding interactions of relebactam with the protein main chain are 978 
shown as dashes with distances in Å. Water molecules are shown as red spheres; those that 979 
make conserved interactions are numbered. (A) CTX-M-15 (16-hour soak) showing 980 
relebactam bound in two conformations; (B) L2 (16-hour soak); (C) KPC-4 (1-hour soak). 981 
Relebactam was modelled as both the imine (desulfated, ‘acyl’ -98 as shown in Figure 5A) 982 
and ‘intact’ forms from 16-hour soaks of (D) KPC-2, (E) KPC-3 and (F) KPC-4 crystals.  983 
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 985 
Figure 5: Time-Dependent Fragmentation of Covalent Avibactam and Relebactam 986 
Adducts. A) Chemical structures of proposed intermediates upon carbamylation and 987 
fragmentation pathways. B)-G) Deconvoluted ESI-MS spectra showing covalent 988 
modifications of KPC variants (KPC-2 -4) by DBOs over time. Enzymes were incubated with 989 
2 equivalents of avibactam or relebactam in 50 mM Tris-HCl pH 7.5 at room temperature. 990 
Data are shown after maximum entropy deconvolution (MassHunter Qualitative Analysis 991 
software V.7 (Agilent Technologies)) over the mass range 1200-2000 Da.  992 
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